title: Therapeutic innovations in endocrine diseases - Part 4 : Pasireotide: Long-acting release somatostatin analogue.
abstract: Pasireotide, the latest long-acting release somatostatin analogue, is distributed more widely to the various somatostatin receptors, which theoretically increases its strength and broadens its scope. Does this reflect genuine therapeutic progress? Or rather does its reduced specificity cause too many adverse reactions to make it a significant therapeutic achievement?
authors.affiliation: Université de Lille 2, CHRU de Lille, Clinique endocrinologique Marc-Linquette, 59037 Lille cedex, France. Electronic address: jl-wemeau@hotmail.fr.
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Wémeau
mesh_terms: D000172:Acromegaly / Q000188:drug therapy*; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D047748:Pituitary ACTH Hypersecretion / Q000188:drug therapy*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D003692:Delayed-Action Preparations; D006728:Hormones; D013004:Somatostatin; C517782:pasireotide